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Background: Therapeutic options in IgAN are still limited. The aim of this study is to explore the feasibility of using
endothelial progenitor cell to treat IgAN in rat model.
Methods: Rat bone marrow mononuclear cells (BM-MNCs) obtained with density gradient centrifugation were
cultured in vitro, and induced into endothelial progenitor cells (EPCs). EPCs were identified by surface marker CD34,
CD133 and VEGFR2 (FLK-1) and by Dil-Ac-LDL/FITC-UEA-1 double staining. EPCs were labeled with PKH26 prior to
transplantation. Rat model of IgAN was established by oral administration of bovine serum albumin together with
lipopolysaccharide via the caudal vein and subcutaneous injection of CCL4. Kidney paraffin sections were stained by
H&E and PAS. Immunofluorescence was used to assess IgA deposition in the glomeruli. Peritubular capillary (PTC)
density was determined by CD31 staining. Monocyte chemoattrant protein-1 (MCP-1), hypoxia-inducible factor-1α
(HIF-1α) and CD105 were also measured by immunohistochemistry, western blotting and real-time fluorescent
quantitative PCR.
Results: The transplanted BM-EPCs were successfully located in IgAN rat kidney. After transplantation, Urinary red
blood cell, urine protein, BUN, Scr and IgA serum level were significantly decreased, so were the areas of glomerular
extracellular matrix and the IgA deposition in the glomeruli. In addition, PTC density was elevated. And the
expression levels of HIF-1α and MCP-1 were significantly down-regulated, while the expression of CD105 was
up-regulated. All these changes were not observed in control groups.
Conclusion: The BM-EPCs transplantation significantly decreases the expansion of glomerular extracellular
matrix and the deposition of IgA in the glomeruli; lowers the expression of inflammatory factors; increases
PTC density; improves ischemic-induced renal tissue hypoxia, all of which improves the renal function and
slows the progress of IgA nephropathy.
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IgAN, the most common form of glomerular disease
throughout the world, was first reported by Berger and
Hinglais in France in 1968 [1]. 25% patients with IgAN
will develop end stage renal diseases (ESRD), 5–25 years
after the diagnosis of IgAN. However, the cause of pri-
mary IgAN and the mechanism defining mesangial IgA
deposition in IgAN are unclear, and thus there has been
no effective therapeutic treatment for patients with
IgAN so far.* Correspondence: fengjiangm@163.com
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unless otherwise stated.Glomerulosclerosis and interstitial fibrosis are irrevers-
ible pathological changes during the development of
IgAN to ESRD. Therefore, the focus of our research on
how to delay the progress of renal fibrosis in IgAN pa-
tients. Previous studies have shown that in IgAN pa-
tients, cell damage and apoptosis of renal microvascular
endothelial cells and loss of PTC cause renal ischemia,
hypoxia, activation of stromal cell, secretion of fibrosis
cytokines, which leads to the upregulation of fibrosis-
related genes and accumulation of extracellular matrix
(ECM) [2-5]. In 1997, Asahara et al. [6], for the first
time, isolated and confirmed the existence of endothelial
progenitor cells, which can differentiate into vascular. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Sequences of amplification primers for CD105,
MCP-1, HIF-1 and β-actin
Name Sequence (5′¬3′) Tm (°C) Size (bp)
CD105 F ACTCGGGAGGTGTTTCTGGTCTT 63.1 211
CD105 R GTGCTGCTATGGAGGTAATGGTG 61.4
MCP-1 F TGAGTCGGCTGGAGAACTACAAG 61.3 209
MCP-1 R AGGTGCTGAAGTCCTTAGGGTTG 61.7
HIF1-αF GCCTTAACCTATCTGTCACTTTG 55.9 250
HIF1-αR ATTGTCTTCTGCTCCATTCCAT 58
β-actin F GGAGATTACTGCCCTGGCTCCTAGC 60.1 155
β-actin R GGCCGGACTCATCGTACTCCTGCTT 62
Table 2 Biochemical factors of normal and IgAN rats
groups (x ± s)
Normal Group IgAN Group
Weight (gram) 237.0 ± 9.7 204.5 ± 7.1*
Urinary red blood cell count (cells/μL) 4.82 ± 1.6 422.12 ± 49.65*
Urine Protein (mg/24 h) 9.94 ± 4.03 70.3 ± 33.2*
BUN (mmol/L) 6.57 ± 0.49 10.42 ± 1.32*
Scr (μmol /L) 26.8 ± 3.89 52.8 ± 6.76*
Serum IgA(μg/ml) 26.04 ± 1.12 28.99 ± 1.30*
ALT (u/L) 34.17 ± 3.87 40.17 ± 5.74
AST (u/L) 85.67 ± 11.65 90.5 ± 13.05
GGT (u/L) 28.0 ± 5.59 28.17 ± 5.53
ALB (g/L) 40.67 ± 4.72 38.0 ± 4.29
*P < 0.01, compare to normal group.
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Currently, most studies suggest that the EPC is mainly de-
rived from umbilical cord blood, adult bone marrow and
peripheral blood [7]. Therefore, the aim of our study is to
investigate whether BM-EPCs transplantation will be an
effective therapeutic mean for IgAN patients.
Methods
Animal
The China medical university animal care and use Com-
mittee approved the procedures.
Female Sprague–Dawley (SD) rats, weighted 150–200
gram, were used in this study. The rats were maintained
under a 12 hour light/dark cycle at a constant temperature
(22 ± 1°C), with free access to clean water and normal chow.
The rats were orally administrated with BSA (MBCHEM,
USA) at dosage of 400 mg/kg, continuously for 6 weeks. At
the 6.8th week, the rats received lipopolysaccharide (LPS)
(AMRESCO Inc, Solon, OH, USA) injection via the caudal
vein, at a dose of 0.25 mg/kg. Then, the rats were received
subcutaneous injection of 0.4 ml castor oil and 0.1 ml car-
bon tetrachloride (CCL4) once a week, continuously for
9 weeks as described before, with slight modification [8-10].
To minimize the effect of CCL4 on liver, the dosage of CCL4
was reduced to one third of the dosage used for establish-
ment of hepatic fibrosis
The IgAN rats were identified by measuring 24-hour
urine protein, Urinary red blood cell, blood urea nitro-
gen (BUN), serum creatinine (Scr), as well as level of
IgA. Meanwhile, Liver function was monitored by Ala-
nine amino transferase (ALT), aspertate amino- transferase
(AST) and γ-glutamyl- transferase (GGT) were tested.
Each kidney was divided into 2 parts. The first part was
embedded in paraffin and stained with hematoxylin and
eosin (H&E). The second portion was embedded in OCT
and stored at −70°C followed by frozen sectioning for im-
munofluorescence staining. Direct immunofluorescence
(FITC-conjugated rabbit anti-rats IgA antibody from Dako,
USA) was used to visualize the IgA deposition in the glom-
eruli. The IgA deposition was graded by a 5-stage semi-
quantitative method (− to++++): (−), no staining under
low magnification and possible staining under high magni-
fication; (+), possible staining under low magnification and
staining under high magnification; (++), staining under low
magnification and clear staining under high magnification;
(+++) clear staining under low magnification and bright
staining under high magnification; (++++), very intense
staining under high magnification. Then, the IgAN model
rats were randomly divided into two groups: IgAN group
(IgAN+ saline group, 6 rats) and EPC group (IgAN +
endothelial progenitor cells, 30 rats). Normal rats receiving
saline (n = 6) were used as control group. The study was
approved by the Academic Review Board at China Medical
University (see Additional file 1).Culture and identification of EPCs
EPCs were isolated and prepared by using the density
gradient method, according to the previous description
[6,11,12]. The femur and tibia of SD rats were separated
under sterile conditions, from which bone marrow mono-
nuclear cells were isolated. At 37°C 5% CO2 incubator, the
cells were seeded in 6-well plates, at 5 × 105 cells/well, in
M199 medium supplied with VEGF 10μg/L, β-FGF 5μg/L,
EGF 5μg/L, IGF5μg/L, 10% fetal bovine serum (HyClone
Inc., Logan, Utah, USA). At day 14, the cells became
spindle- shaped. The expression of CD34 (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, USA), CD133
(Abnova Inc., Taipei, China) and VEGFR2 (Peprotech,
Rocky Hill, NJ, USA) were identified by flow cytometer
(BD Inc., San Jose, CA, USA). The EPCs were selected
by Dil-ac-LDL/FITC-UEA-1(Molecular Probes, Eugene,
OR) dual staining, and were labeled by PKH26 before
prior to transplantation.
Transplantation of EPCs
EPCs were injected 3 days after the induction of lgAN.
EPC group rats received 3 × 106 cells per rat via the cau-
dal vein (0.5 ml/rat). Other rats received same volume of
Figure 1 Histopathology of kidney sections from control and IgAN rats. The renal sections were stained by H&E staining (A, B) and IgA
antibody followed by FITC 2nd antibody (C, D), respectively.
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7, 14 days after transplantation and 1 day before trans-
plantation. Rats of other groups were sacrificed at 14 days
after transplantation. 24 hour urine protein, Urinary red
blood cell, BUN and Scr were examined for all rats. EachFigure 2 The morphological changes of cultured endothelial progeni
cells were small-round-shaped; Day-3, cells enlarged; Day-7, cells were shor
number of cells increased; Day-21, cells grew with a “cobblestone” appearakidney was divided into three parts: one for pathological
analysis and immunohistochemistry studies; The second
portion was embedded in OCT for immunofluorescence
staining; The third part was saved in liquid nitrogen for
western blotting and real time RT-PCR.tor cells (EPCs). All images were taken under light microscope. Day-1,
t spindle sharped; Day-14, cells became slender-spindle-shaped and
nce.
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studies
The renal tissues were embedded in paraffin. The sec-
tions were cut at 3–4 μm thickness, and stained with
H&E and PAS. Five pictures were taken randomly for
each PAS-stained section at 400× magnification, and
were analyzed by MetaMorph software (UIC) to calcu-
late the ratio of glomerular ECM area and total glomeru-
lar area, which was used as the thickness index of
glomerular mesangial matrix. Immunohistochemical stain-
ing on renal section was performed with ABC method.
Polyclonal antibodies against CD31, HIF-1α, MCP-1 and
CD105 were purchased from Bioss Inc. (Beijing, China).
Five pictures were randomly taken for each section at 400×
magnification, and integral optical density (IOD) was cal-
culated by microscopic image analyzer (MetaMorph/
DP10/BX41, UIC/Olympus, USA/Japan). IOD value of
CD31 (endothelial cell-specific marker) was used to
represent the PTC density.
Western blotting assay
The total protein was extracted from renal tissue by RIPA
lysis buffer (Beyotime Inc., Shanghai, China), and sepa-
rated by 10% SDS-PAGE. Then, the separated proteinFigure 3 Identification of EPCs. The cells were collected and analyzed by
cells was indicated as percentage number in figures (A). The cells were also
Merged images showed that most cells were dual-postive. Dual-postive cewas transferred to nitrocellulose membrane (70 V for
1.5 hours). The blots were blocked in 5% non-fat milk
for 1 hour at room temperature, and then incubated
with primary antibodies (HIF-1α, 1:500; MCP-1, 1:500;
CD105, 1:400) overnight at 4°C. At the second day,
horseradish peroxidase labeled secondary antibody (goat
anti-rabbit IgG- HRP, 1:1000) were incubated with the
blots at room temperature for 2 hours. Then, the blots
were washed and incubated with NBT/BCIP for 10–30
mins. The blots were then scanned and analyzed by Gel-
Pro Analyzer software (Media Cybernetics, Silver Spring,
MD). The relative expression levels were quantified and
normalized to control groups.
Real-time fluorescent quantitative RT-PCR
Total RNA extracted by TRIzol extraction (Tiangen Inc.,
Nanjing, China) of kidney homogenates, and quantified
by UV spectrophotometer. Purity of RNA was identified
by A260/A280 ratio and gel electrophoresis. Primers for
CD105, MCP-1, HIF-1α and β-actin (internal control)
were designed with Primer Premier 5.0 software (Palo Alto
CA, USA) as shown in Table 1. 2 μg of total RNA were
reverse-transcribed into cDNA by using TIANScriptcDNA
Kits (Tiangen Inc., Nanjing, China). Real-time quantitativeflow cytometer for CD34, CD133 and FLK-1. The population of positive
fixed and dual stained with DiL-acLDL (red)/ FITC-UEA-1 (green).
lls were defined as EPCs (B).
AB
Figure 4 Immunostaining of PKH26 on tissues from IgAN rats after EPCs transplantation. In kidney tissue, the white arrows indicate the
location of glomeruli. The intensity of PKH26 positive signal were quantified With MetaMorph software, and presented in column graph (bottom
right). *P < 0.05, **P < 0.01, comparing to pre- transplantation, #P < 0.05, comparing today-1 (A). PKH26-positive signal in the liver tissue (B).
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Table 3 Biochemical parameters of Normal, IgAN and
EPCs rats groups (x ± s)
Normal
group
IgAN group EPCs group
Urine Protein (mg/24 h) 9.94 ± 4.03 77.7 ± 17.1 28.16 ± 8.04*#
Urinary red blood cell
count(cells/μL)
5.17 ± 0.79 454.35 ± 72.3 323.68 ± 32.64**
BUN (mmol/L) 6.57 ± 0.45 11.02 ± 1.37 7.88 ± 0.36*#
Scr (μmol/L) 26.8 ± 3.53 55.4 ± 6.02 35.6 ± 5.91*#
Serum IgA(μg/ml) 26.37 ± 2.49 31.72 ± 3.73 27.73 ± 1.65**
ALT (u/L) 33.67 ± 4.76 33.33 ± 3.82 35.82 ± 5.71
AST (u/L) 86.0 ± 8.07 86.5 ± 6.65 88.1 ± 6.69
GGT (u/L) 25.5 ± 3.27 27.0 ± 2.19 27.17 ± 2.48
ALB (g/L) 37.67 ± 2.16 40.17 ± 2.32 39.23 ± 2.49
*P < 0.01, **P < 0.05, compare to IgAN group;
#P < 0.01, compare to Normal group.
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(Clontech, Mountain View, CA) in 20 μl volume, in the fol-
lowing condition: 95°C × 5 s, 60°C × 20s, 72°C × 30 s, for
40 cycles. Each sample was measured three times, and the
average of Ct was taken. The relative expressions of mRNA
were measured using 2−ΔΔCt method.
Statistical analysis
Data was analyzed with one-way ANOVA analysis of
variance using SPSS software 17.0 (IBM, Armonk, NY,
USA). Data were presented as the mean ± S.E.M of at
least three measurements. P < 0.05 was considered as
significant in comparison with control.
Results
Characterization of IgAN animal model
We examined the physical appearance and biochemical
parameters in the rats. IgAN rats were found to show
grey hair and slow-growing. 24-hour urine protein, Urin-
ary red blood cell, BUN, Scr and IgA serum level were
significantly elevated in IgAN rats. ALT, AST and GGT
showed no significant change in IgAN rats after treat-
ment compare to controls. (Table 2) Immunofluores-
cence studies showed that deposition of IgA was mainly
seen at glomerular mesangial area, most of the staining
in the IgAN model group was ++ to +++ (Figure 1).Table 4 Biochemical parameters in EPCs group after transplan
Day-0 Day-1
Urine Protein (mg/24 h) 70.3 ± 33.2 65.44 ± 1
Urinary red blood cell count(cells/μL) 452.72 ± 45.8 444.5 ± 42
BUN (mmol/L) 10.42 ± 1.18 10.06 ± 0
Scr (μmol/L) 52.8 ± 6.05 52.6 ± 9.
Serum IgA(μg/ml) 30.37 ± 1.74 29.72 ± 2
Comparing to Day-0: #P > 0.05, *P < 0.05, **P < 0.01. Day-0 is the EPCs rats before reIdentify EPCs
The freshly isolated EPCs were small-round shaped
and suspended in culture medium. At day 2, cells
started to attach to the dish wall, and cellular hyper-
trophy was observed at day 3, followed by becoming
short spindle shaped. The cellular growth peak was
reached after 7-day culture. At day 10–14, the cells be-
came slender-spindle-shaped and started colony for-
mation. At day 21, cell colony formation was completed
with a “cobblestone” appearance, as shown in Figure 2. At
day 14, EPCs were identified by CD34, CD133, FLK-1
using flow cytometer. DiL-acLDL (red)/FITC-UEA-1
(green) dual staining cells were observed under the laser
scanning confocal microscopy. The cells with dual stain-
ing (shown as yellow fluorescence) were considered as dif-
ferentiating EPCs (Figure 3).
The expression of PKH26
Cryo-section of kidney and liver tissues stained with
PKH26 and incubated with 4′, 6-diamidino-2-phenylindole
(DAPI). PKH26 positive cells showed red fluorescence, nu-
clei were stained blue with DAPI under fluorescence mi-
croscopy. 1 day after transplantation, PKH26 positive cells
were detected in the kidney of EPCs rats, mainly in the
interstitial area. 3, 7, 14 days after transplantation, more
and more PKH26 positive cells were discovered in glom-
erular and interstitial areas. The intensity of red fluores-
cence was gradually increased after transplantation. The
difference between day-1 and day-14 after transplantation
was significant. In addition to the kidney, PKH26-positive
signal could also be detected in the liver tissue. The signifi-
cance of this liver migration of EPCs was still waited to be
investigated (Figure 4).
Biochemical examination
24-hour urine protein, Urinary red blood cell, BUN, Scr
and IgA serum level in IgAN group increased signifi-
cantly compared to the ones in normal group. However,
these parameters in EPCs group decreased compared to
the ones in IgAN group. The differences between groups
were statistically significant (p < 0.01, Table 3). After
transplantation, 24-hour urine protein, Urinary red blood
cell, BUN, Scr and IgA serum level gradually decreased.
The differences between 14 days post-transplantation andtation (x ± s)
Day-3 Day-7 Day-14
6.9# 54.22 ± 16.2# 28.86 ± 8.56* 28.16 ± 8.0*
.13# 432.88 ± 31.5# 406.9 ± 27.01# 323.68 ± 32.64*
.87# 9.6 ± 0.85# 8.76 ± 0.82* 7.88 ± 0.36*
07# 45.2 ± 7.79# 38.4 ± 6.73* 35.6 ± 5.91**
.24# 28.88 ± 1.82# 28.32 ± 1.87# 27.73 ± 1.65*
ceiving EPCs transplantation.
Figure 5 Representative images of histological staining of renal sections. The renal sections were stainied by H&E staining (A, B, C) , PAS
staining (D, E, F) and Immunofluorescence staining for IgA (G, H, I), respectively. Normal group, there was no significant histological abnormality
after saline solution injection (A, D, G), IgAN group after saline solution injection, the pathological changes were increased number of cells in the
glomeruli, and moderate to severe hyperplasia of mesangial matrix and cells. There was significiant green fluorescence in the glomeruli.
(B, E, H). EPCs group after EPCs transplantation, hyperplasia of mesangial matrix and cells was decreased, green fluorescence in the
glomeruli was weaken than IgAN group, (C, F, I).
Table 5 The ratio of ECM to total glomerular area (ECM/
TGA) and PTC density in normal/IgAN/EPCs group (x ± s)
Normal group IgAN group EPCs group
ECM/TGA(%) 0.44 ± 0.58 11.06 ± 1.4# 5.59 ± 1.94*#
PTC density (A) 44.75 ± 10.26 17.93 ± 4.15# 30.9 ± 3.37*#
*P < 0.01 compare to IgAN group; #P < 0.01compare to normal group.
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(p < 0.01, Table 4).
Pathological observation of kidney
Morphology of glomerular, tubular, and renal interstitial
remainined normal in normal group. While, in IgAN
groups, the number of glomerular mesangial cells in-
creased, mesangial matrix widened, the shape of renal
tubules became irregular. In EPCs group, pathological
changes of renal mesangial matrix and tubules were sig-
nificantly alleviated (shown in Figure 5).
The PAS staining showed that in IgAN group, the ratio
of ECM area and the corresponding glomerular area was
significantly higher than the ratio in normal group (p <0.01), suggesting the accumulation of renal glomerular
ECM. However, in EPCs group, the deposition of renal
glomerular ECM decreased significantly, shown by lower
ratio of ECM area and the corresponding glomerular
area (p < 0.01) (Figure 5 and Table 5).
Figure 6 Immunohistochemical detection of CD31 , MCP-1, CD105 and HIF-1a. Normal group, CD31-positive endothelial cells were regularly
distributed in renal interstitium (A); The expression of CD31 was significantly decreased in IgAN group (B); In EPCs group, the expression of CD31
was also decreased than the normal group,however, it was significantly increased compared to the one in IgAN group. (C). In normal group,
MCP-1 staining was barely detectable in renal tubular epithelial cells (D); However, in IgAN group, the enhanced expression of MCP-1 was
detected. (E); MCP-1 expression gradually decreased in EPCs group (F). Normal group, CD105 staining was weak. (G); IgAN group, the
expression of CD105 was significantly elevated. (H); CD105 expression in EPCs group after transplantation. (I). In normal group, minimal
HIF-1α was detected in renal tubular epithelial. (J); The expression of HIF-1α increased significantly in IgAN group, (K); It gradually decreased in EPCs group
(L). Immunohistochemistry of CD31 (A, B, C); Immunohistochemistry of MCP-1 (D, E, F); Immunohistochemistry of CD105 (G, H, I); Immunohistochemistry
of HIF-1α (J, K, L).
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Immunofluorescence staining of IgA showed slight IgA
deposition in normal rats and the fluorescence intensity
was scored as “–” to “+”. In contrast, IgAN rats had sig-
nificant granule-like green fluorescence in the glomeruliwhich was scored as “++” to “++++”, these results indi-
cated successful establishment of IgAN. EPC rats had
significantly reduced green fluorescence in the glomeruli
which was scored as “+” to “+++” compare to IgAN rats
(Figure 5).
Table 6 The ratio of ECM to total glomerular area (ECM/TGA) and PTC density in EPCs group after transplantation
(x ±s )
Day-0 Day-1 Day-3 Day-7 Day-14
ECM/TGA(%) 11.06 ± 1.94 10.57 ± 1.8# 8.94 ± 1.71* 8.62 ± 1.13** 6.05 ± 1.49**
PTC density (A) 13.69 ± 3.54 14.96 ± 3.34# 19.26 ± 3.01* 24.62 ± 3.88** 30.9 ± 3.37**
Comparing to Day-0: #P > 0.05,*P < 0.05,**P < 0.01. Day-0 is the EPCs rats before receiving EPCs transplantation.
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In normal group, CD31 was shown as brown fine de-
posits on the membrane of endothelial cells of PTC,
which were distributed in renal interstitium among renal
tubules; some was shown on the membrane of glomeru-
lar vascular endothelial cells. The expression of CD31
was significantly decreased in IgAN group as a compari-
son to the normal group, while the expression of CD31
in EPCs group was significantly increased compared to
the one in IgAN group. Integrated optical density (IOD)
value of CD31 was used to represent the density of peri-
tubular capillary. The difference between groups was sta-
tistically significant (Figure 6, Tables 5 & 6).
In normal group, MCP-1 staining was barely detect-
able in renal tubular epithelial cells. However, in IgAN
group, the enhanced expression of MCP-1 was detected.
After EPCs transplantation, MCP-1 expression gradually
decreased at day-3, day-7 and day-14 (Figure 6).
In normal group, CD105 staining was weak in stromal
vascular endothelial cells and glomerular/interstitial
cells. While in IgAN group, the expression of CD105 was
significantly elevated prior to transplantation. CD105 ex-
pression in EPCs group diminished at day-3 after EPCs
transplantation, while it increased at day 7 and day 14
(Figure 6).
In normal group, minimal HIF-1α was detected in
renal tubular epithelial. The expression of HIF-1α in-
creased significantly in IgAN group, while it gradually
decreased in EPCs group (Figure 6).Figure 7 Protein expression of MCP-1, CD105 and HIF-1α after transp
densitometry analysis (B, from 5 experiments) demonstrating protein expre
normal, IgAN and EPCs groups.*P < 0. 05 vs normal,#P < 0.05 vs IgAN.Protein and mRNA levels of MCP-1, HIF-1α and CD105
To confirm the expression prolife of the molecules we
observed in immuno- histochemistry studies, we mea-
sured the expression again by using quantitative western
blotting or quantitative RT-PCR. Similarly, we found
that normal group express relatively less amount of
MCP-1, HIF-1α, which were significantly higher in IgAN
groups. However, after EPC transplantation, MCP-1,
HIF-1α expression was gradually decreased in 14 days.
The protein expression of CD105 was decreased in the
first 3 days after transplantation, while it increased in
day-7 and day-14. mRNA of these molecules showed
the similar results. mRNA levels of MCP-1 and HIF-1α
were significantly increased in IgAN group, while the
levels were gradually decreased in 14 days after trans-
plantation. CD105’s mRNA first increased in the first
7 days after transplantation, but it increased and reached
the peak at day-14 (Figures 7, 8 & 9).
Discussion
Currently, IgAN is considered as a very severe immune
disease, on which there is no proper and successful
treatment. Our research aims to control or improve the
pathogenesis of renal tissue in IgAN rat model, by
PKH26-labeled EPCs transplantation. IgAN rat model
was established by a combined injection of USA, LPS
and CCL4. Hematuria and proteinuria were observed in
the treated rats at 6 weeks post-injury and some of IgAN
rats developed gross hematuria (data not shown). Obviouslantation. Representative immunoblots (A) and quantitative
ssion of MCP-1, CD105 and HIF-1α, in the renal cortex of rats from
Figure 8 Protein expression of MCP-1, CD105 and HIF-1α during transplantation. Representative immunoblots (A) and quantitative
densitometry analysis (B, C, D) for protein expression of MCP-1, CD105 and HIF-1α, in the renal cortex of rats from normal, day-0, day −1, day-3,
day-7 and day14 EPCs rats after transplantation. *P < 0.05, **P < 0.01, comparing to the day-0 group.
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also been detected. These findings indicate a successful es-
tablishment of IgAN model in rats. One day after the
transplantation, the PKH26-labeled cells started to express
mainly in renal interstitial area. At the day 3, 7, 14, the
number of PKH26-labeled cells in the renal interstitial
and glomerular area gradually multiplied, indicating that
intravenous injected BM-EPCs can be re-located to the
damaged kidneys. It was observed that urinary red blood
cell, 24- hour urine protein, BUN and Scr dramatically de-
creased as well as the improvement of renal pathological
findings in EPCs group comparing to IgAN group. Other
markers, such as HIF-1α and MCP-1 expression increased
in IgAN group but decreased in EPCs group. While
CD105 was an exception, the expression of CD105 sus-
tained at a high level when EPCs were transplanted. All
these data suggested that BM-EPCs transplantation sig-
nificantly decreases the levels of inflammatory factors, and
improved ischemic- induced renal tissue hypoxia.
The conventional immunosuppressive treatment, such
as the corticosteroid and cytotoxic drugs, the application
of ACEI and ARB have been introduced into thetreatment of IgAN for many years, however, all these
methods are not effective, especially for IgAN patient’s
prognoses [13,14]. Among all the factors which affect
IgAN prognoses, renal interstitial fibrosis is one of the
most independent risk factors. PTC provides the major
blood supply for renal tubule-interstitium; and much evi-
dence has suggested that loss of PTC is mainly due to is-
chemic injury and fibrosis of renal tubule-interstitium.
One major feature of PTC pathology is the decreased
number of capillary endothelial cells. Therefore, repair or
regeneration of endothelial cells and reducing microvascu-
lar loss will be the promising therapeutic treatment for
IgAN. Endothelial progenitor cell-mediated therapeutic
angiogenesis could be an effective way to control or im-
prove a wide variety of pathological condition. In recent
years, EPCs therapy has become a hot spot in the treat-
ment of heart disease, stroke, peripheral arterial disease,
rheumatism, cancer and other diseases [15-18]. In our la-
boratory, recent data showed that the cell number of bone
marrow EPCs in IgAN rats was signficantly less than that
of normal rats by 33.3%; the migration rate of these cells
in IgAN rats was decreased by 10%; the proliferation rate
Figure 9 mRNA level of MCP-1, CD105 and HIF-1α. Real-time quantitative RT-PCR analysis of MCP-1, CD105 and HIF-1a mRNA after
transplantation. **P < 0. 05 vs normal, *P < 0.05 vs IgAN. (A). MCP-1, CD105 and HIF-1a mRNA from the renal cortex of rats isolated from
normal, day-0, day −1, day-3, day-7 and day14 EPCs rats after transplantation. *P < 0.05,**P < 0.01, comparing to the day-0 group (B, C, D).
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tically significant comparing to that of normal rats (un-
published data). To continue the studies, here we tried to
treat IgAN rats with exogenous EPCs transplantation. The
results showed that BM-EPCs can re-locate in the kidney
of IgAN rats. The IgAN rats receiving EPCs have signifi-
cantly improved kidney function, reduced expansion of
glomerular extracellular matrix, attenuated IgA deposits
in the glomeruli and increased density of peritubular
capillary.
CD105, known as endoglin, is a type-I glycoprotein on
cellular membrane. CD105 is predominately expressed
in vascular endothelial cells and related tissues, while is
absent in lymphatic endothelial cells [19]. Different from
pan-vascular endothelial cell markers, CD105 is only
strongly expressed in highly proliferating vascular endo-
thelial cells, while weakly or not expressed in vascular
endothelial cells in normal adult tissues. Other re-
searchers have found that in the case of inflammation
occurring on skin lesion, the up-regulation of CD105
promptly accelerated the infiltration of inflammatory
cells and angiogenesis [20]. Our research also showed
the higher expression of CD105 in the kidney tissue of
IgAN rats, which might due to the elevated inflamma-
tory responses in IgAN rats. CD105 expression de-
creased 3 days after EPCs transplantation, indicating thereduced inflammatory responses. At the day-7 and day-
14 after transplantation, CD105 level increased gradually
comparing to the day-3. We speculate this change might
due to the process that relocated EPCs were transformed
into actively proliferating vascular endothelial cells.
Another marker for vascular endothelial cells is CD31,
which is highly expressed at the cellular junctions be-
tween vascular endothelial cells. Therefore, in this study,
the number of CD31 positive cells was used to represent
PTC density. In our research, CD31 positive staining
was dramatically decreased in the kidney tissue of IgAN
group comparing to that of normal group, indicating a
decreased PTC. 7 and 14 days after transplantation, in
EPCs group, the number of CD31 positive cells was in-
creased, suggesting an increasing PTC density in EPCs
group comparing to that in IgAN group.
Previous studies have shown that hypoxia is a major
factor for cellular damage and angiogenic dysregulation.
Hypoxia can induce the expression of certain genes and
then affect cellular function, which is one of the import-
ant mechanisms for the initiation and development of
renal interstitial fibrosis [21-23]. The declining of PTC
density often leads to tubule-interstitial in a hypoxic
state. Hypoxia-inducible factor 1-α (HIF-1α) is a tran-
scription factor in cells growing at low oxygen concen-
tration, which plays an essential role in cellular and
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1α is often used as a sensitive indicator for hypoxia. Our
study showed that HIF-1α expression increased in the
kidney tissues of IgAN rats, while decreased in EPCs rats
(p < 0.05), indicating that EPCs transplantation could
improve hypoxic condition of tubule-interstitial. This re-
sult is consistent with the observation that PTC density
was increased in EPCs rats.
MCP-1 is an inflammatory chemokine. Local overex-
pression of MCP-1 at vessel wall induces infiltration and
aggregation of mono-nuclear cells, and cause formation
of atherosclerotic lesion [26]. It also promotes the ex-
pression of important cytokines which cause fibrosis,
such as IL-6, TGF-β, etc. In kidney, overexpression of
MCP-1 results in the accumulation of extracellular matrix
in glomerular and tubules, causing glomerulosclerosis and
renal interstitial fibrosis, eventually leading to renal failure
[27]. Only trace expression of MCP-1 was detected in
renal mesangial cells, renal tubular epithelial cells, vascu-
lar endothelial cells and other cells under normal circum-
stances. However, MCP-1 is induced and highly expressed
under many other conditions, such as hypoxia, immune
responses, viral infection, injury, hemodynamic changes,
etc. [28,29], which is in agreement with our observation.
We found that MCP-1 expression was enhanced in the
kidney of IgAN group comparing to the normal group,
while it declined after EPCs transplantation. The differ-
ences between day-7/14 and day-prior-to transplantation
were statistically significant.
In IgAN pathogenesis, ECM expansion or mesangial
proliferation is often associated with serum elevation of
IgA-IgG2a IC and enhanced deposition of IgA, as well
as cytokine production such as IL-6 and TGF-β. There-
fore, in this study the ratio of the ECM area to glomeru-
lar cross-sectional area was determined to represent the
degree of nephropathy in IgAN experimental rats. We
found that this ratio was significantly decreased in EPCs
transplanted rats, comparing to IgAN group, suggesting
that EPCs transplantation can cause a decline in the de-
position of ECM in mesangial area. It’s been known that
the increased synthesis and declined degradation of
ECM are the important factors causing the development
of glomerulosclerosis [30-32]. Therefore, in theory, EPC
transplantation may further delay the progress of glom-
erular sclerosis, which may need further investigation.
In summary, our findings suggested that BM-EPCs
were re-located to the damaged kidneys and improve the
pathogenesis of renal tissue in IgAN rat. It seemed pro-
vided a practically effective way for treating IgAN
patients.
Conclusion
EPCs transplantation in IgAN rats promotes angiogenesis,
resulting in an increased PTC density. It also significantlydown-regulates HIF-1α, MCP-1 expression, relieves tissue
ischemia, improves hypoxia and inflammatory infiltration.
In transplanted IgAN rats, the expansion of extracellular
matrix in glomerular was reduced; renal pathogenesis pro-
gression was slowed, and renal function was improved. All
these data establish the experimental fundament for the
new therapies of IgAN.
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